The first authorized generic versions of Noxafil® (posaconazole) 200mg/5mL oral suspension have been made available in the US. Both Hikma Pharmaceuticals and Par Pharmaceuticals announced they will be supplying the product.
Posaconazole, an azole antifungal, is indicated for:
- Prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-vs-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy in adult and pediatric patients 13 years of age and older.
- Treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole in adult and pediatric patients aged 13 years and older.
Posaconazole oral suspension is not substitutable with posaconazole delayed-release tablets or posaconazole powder for delayed-release oral suspension due to the differences in the dosing of each formulation.
- Hikma launches Posaconazole Oral Suspension in the US. News release. Hikma Pharmaceuticals. Accessed April 3, 2023. https://www.hikma.com/newsroom/article-i6264-hikma-launches-posaconazole-oral-suspension-in-the-us/.
- Endo launches authorized generic version of Noxafil® (posaconazole) Oral Suspension. News release. Endo International plc. Accessed April 3, 2023. https://investor.endo.com/news-releases/news-release-details/endo-launches-authorized-generic-version-noxafilr-posaconazole-0.